16 results about "Blood disease" patented technology

The invention provides a semantic search method and system for blood disease medical record big data, and relates to the technical field of medical information processing.The method comprises the steps that firstly, a blood disease medical record semantic association network is constructed, medical record text units serve as nodes, semantic association relationships serve as edges, and related information of the nodes and the edges is marked; analyzing a user search intention to generate a search semantic vector, calling semantic association network information to perform dynamic semantic matching to obtain a matched medical record text unit set, generating a hierarchical search result according to a matching result, dividing and sorting according to a matching dimension, and generating semantic association interpretation; and finally, based on the access behavior feedback of the user to the hierarchical search result, optimizing the semantic association network, recording user clicking, staying and secondary search triggering conditions, and adjusting the node association priority, edge association strength and weight to improve the accuracy and practicability of blood disease medical record search.

The present invention relates to nicotinamide mononucleotide derivatives of Formula (I)for use in the treatment and / or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and / or prevention of a red blood cell disorder, especially sickle cell disease.

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, Y1, Y2, Y3, Z1, Z2 and m are as defined herein.

The invention relates to the technical field of medical equipment, in particular to a portable diagnosis and treatment instrument for blood disease treatment, which comprises a box body and moving wheels, an opening is formed in the upper end of the box body, locking openings are formed in two sides of the top of the box body, and the moving wheels are mounted on the box body; the partition plate is fixedly mounted in the middle of the box body; the access mechanism is installed on the box body, the control end of the access mechanism is arranged outside the box body, and the power output end of the access mechanism is fixedly connected with diagnosis and treatment equipment; the outward pushing mechanisms are fixedly installed on the two sides of the partition plate, extending mechanisms penetrate through the outward pushing mechanisms on the two sides, and one ends of the extending mechanisms are connected with the diagnosis and treatment equipment; the box cover is matched with the opening of the box body, rotary knobs are rotationally installed on the two sides of the box cover, and clamping plates are fixedly arranged on the rotary knobs; and the handle is fixedly mounted on the box cover. The portable diagnosis and treatment instrument for blood disease treatment provided by the invention not only can diagnose and treat blood diseases, but also has better portability, meanwhile, diagnosis and treatment equipment can be quickly taken out or put into the box body, the operation is simple, and the practicability is high.

The application discloses a bone marrow morphology acute event identification early warning system and relates to the technical field of intelligent medical treatment, and the technical solution points are as follows: acquiring bone marrow cell image data, pre-processing, obtaining pre-processed image data; inputting the pre-processed image data into a trained AI model, and outputting a classification prediction result. The application can more accurately identify and classify bone marrow cells by applying a visual Transformer and a visual Mamba model, can identify different cell development stages, and can diagnose various blood diseases through an AI model standardized analysis process, reduce professional barriers in the field of bone marrow morphology, reduce absolute dependence on expert experience, and enable areas with insufficient medical conditions to also obtain high-quality preliminary diagnosis.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The present invention relates to nicotinamide mononucleotide derivatives of Formula (I)for use in the treatment and / or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and / or prevention of a red blood cell disorder, especially sickle cell disease.

The present application relates to the technical field of blood extraction, in particular to a cell separation and extraction device for animal blood disease detection, which comprises a box body, a partition plate is arranged at the bottom of the box body, a cavity is formed between the box body and the partition plate, a centrifugal assembly is arranged in the cavity, and the centrifugal assembly is used for placing test tubes for centrifugal operation, the test tubes after centrifugation are taken out and replaced by collection test tubes, the piston rod at the end of the air cylinder drives the rack to reciprocate in the vertical direction, the rack drives the double-head gear rod to mesh and rotate in the moving process, the double-head gear rod drives the second wedge-shaped plate to reciprocate at a 90° angle in the rotating process, so that the second wedge-shaped plate reciprocally extrudes the first wedge-shaped plate, the air in the rubber head of the suction tube is continuously sprayed out, in the process of air spraying to generate airflow, the airflow pushes and extrudes the cell liquid temporarily stored in the glass tube of the suction tube, so that the cell liquid enters the collection test tube for collection, and the accuracy of animal pathological detection is improved.

The application discloses a kind of based on microfluidic and AI image recognition basophil activation detection method and system.The method comprises: the peripheral blood sample to be measured is injected into the microfluidic chip device containing conical microporous filter membrane and enriched basophil;In reaction cavity, pre-mixed dry CD63-FITC and CD203c-PE fluorescently labeled antibody and allergen stimulant are added;After incubation at 37 DEG C, 512×512 pixel high-resolution image is obtained by digital microscopic imaging system;Improved target detection model is used to identify activated cells, the model uses lightweight FasterNet backbone network and dynamic attention mechanism, generates cell activation heat map by Gaussian kernel density estimation, combines fluorescence intensity weighted calculation activation index and outputs visual report.System includes microfluidic chip module, fluorescently labeled module, temperature control incubation module, image acquisition module, AI analysis module and man-machine interaction module.The application realizes high sensitivity, high specificity and automatic detection, and is suitable for clinical diagnosis of allergic diseases and blood diseases.

A construction method of a blood disease knowledge graph database is characterized by comprising the following steps: determining a target user and a purpose of the database, and defining a concept and a relationship of a blood disease field; blood disease field data are collected and preprocessed; using a natural language processing technology to extract entities, relationships and attributes in the blood disease data text, and establishing relationships among the entities; establishing a blood disease ontology model and designing a database; storing the processed data in a database, designing query and retrieval interfaces, and supporting a user to query and browse a knowledge graph; and verifying the accuracy and integrity of the knowledge graph. According to the method, through the accurate entities and the relation model, the relation among the entities such as diseases, symptoms and treatment methods in the knowledge graph is clearer. The method is helpful for users to better understand related knowledge of blood diseases, and supports clinical decision and research. An effective updating mechanism is constructed, and it is ensured that information in the knowledge graph is synchronized with the latest medical research progress and clinical practice.

This invention relates to the field of medical informatics technology, specifically to a knowledge graph-based auxiliary system for hematological transplantation diagnosis and treatment. The system includes a knowledge graph structure optimization module, a reasoning path constraint module, a candidate solution generation module, a strategy consistency verification module, and a graph repair guidance module. In this invention, by optimizing the structure of the hematological disease knowledge graph, identifying and correcting the feature density and sparse connection regions between nodes, the adaptability and information density of the knowledge graph are enhanced, improving the accuracy and comprehensiveness of the reasoning path, enhancing the medical rationality of decision-making and the accuracy of reasoning, and ensuring the practicality and accuracy of recommended solutions. Combined with candidate strategy generation and consistency verification, the logical closure between strategies is strengthened, ensuring the feasibility and rationality of transplantation diagnosis and treatment strategies. Through graph repair guidance, the structure and integrity of the knowledge graph are optimized, solving the problems of incomplete information and inaccurate reasoning in traditional systems.

The application provides an antibody composition for detecting acute T lymphoblastic leukemia by full-spectrum flow cytometry, a detection system and application thereof, and relates to the technical field of blood disease detection. The antibody composition is two groups of antibodies. The first group is 14 kinds of fluorescein-labeled cell membrane monoclonal antibodies, including anti-CD45, anti-CD99, anti-CD34, anti-CD48, anti-CD2, anti-CD3, anti-CD4, anti-CD5, anti-CD7, anti-CD8a, anti-CD16, anti-CD56, anti-CD94 and anti-TCR gamma delta. The second group is two kinds of intracellular monoclonal antibodies, including anti-nucleus TdT and anti-cytoplasm CD3. The two groups of antibodies are added into the same tube in sequence. The application also provides a flow cytometry sample for detecting acute T lymphoblastic leukemia based on full-spectrum flow cytometry, and a detection analysis method and system, so that the missed diagnosis rate and misdiagnosis rate of T-ALL detection are reduced.

The application relates to a heteroaromatic ring compound with a structure shown in formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule thereof, and a pharmaceutical composition and application thereof. The compound can be used as an FLT3 kinase inhibitor, has excellent anti-proliferation activity on acute myeloid leukemia cells and Ba / F3-FLT3-ITD-TKD stable strain cells containing drug-resistant point mutations, and can overcome the acquired drug resistance of FLT3-F691L of existing clinical drugs. The heteroaromatic ring compound provided by the application can be used for preparing a drug for preventing or treating diseases (such as acute myeloid leukemia) mediated by FLT3 tyrosine kinase, and can be used for treating various malignant blood diseases of human beings and other mammals. (I).

The invention discloses a blood quantitative sampling device for blood disease detection and a detection method, and belongs to the technical field of blood disease detection.The blood quantitative sampling device comprises a fixing base and a fixing frame, a placing table is fixedly connected to the fixing base, and waste liquid cavities are fixedly connected to the two sides of the fixing base; a mounting plate is mounted on a mounting frame, then a torsion block is twisted, a screw rod pushes a movable block, a push groove is promoted to push a connecting rod, then the connecting rod drives a positioning plate to move, the mounting plate is promoted to be embedded into an embedding groove to complete clamping and fixing, and therefore a multi-position sampling structure is constructed; the main sampling cavity, the auxiliary sampling cavity and the secondary sampling cavity are screwed together in a threaded manner, so that the sample storage cavities with different volumes are assembled and built, the sampling quantity requirements of different detection items are met, the sampling mode of a single sample for one time is solved, the repeated operation burden of workers is greatly reduced, and the working efficiency of batch sampling is improved.

This invention proposes a method and system for prognostic analysis of hematological stem cell transplantation based on OCR and NLP technologies. The method includes receiving and recognizing medical reports uploaded by users, recognizing them as raw text through an OCR service, and then converting them into medical text through post-processing. Subsequently, an NLP service is invoked to extract structured patient features, which are then optimized and input into a prognostic prediction model to obtain prediction results for various prognostic indicators. Finally, the outputs of multiple models are merged to generate a visualized prediction report. This invention achieves seamless data linkage and automated flow between modules without human intervention by constructing a fully automated collaborative architecture that integrates medical data uploading, OCR recognition, structured data extraction, AI prognostic prediction, and result output. This eliminates data breakpoints and human errors, solving the technical problems of isolated functional modules and data flow breakpoints in existing technologies. Furthermore, it improves adaptability to medical scenarios.

The invention belongs to the technical field of cell culture, and discloses a bone marrow cell culture medium and a preparation method thereof, and a method for in-vitro culture of bone marrow cells, the bone marrow cell culture medium is composed of a basic culture medium, streptomycin, gentamicin, a platelet lysis buffer, and glutamate enzyme; the final concentration of streptomycin is 50-100 [mu] g / mL, the final concentration of gentamicin is 20-50 [mu] g / mL, the final concentration of platelet lysate is 5-15% (v / v), and the final concentration of glutamate enzyme is 0.1-1 mmol / L. The bone marrow cell culture medium can efficiently support in-vitro proliferation of bone marrow cells, through specific combination and appropriate concentration control of the culture medium, the medium-term cell acquisition amount can be remarkably increased, and medium-term cell chromosomes are complete in morphology and good in dispersity; the standard requirements of clinical bone marrow cell chromosome karyotype analysis, blood disease diagnosis and cell genetics experiments in the scientific research field can be met.